BTG plc (BCG) 2012年年度报告「LSE」.pdf

1、BTG plc Annual Report and Accounts 2012Because peopledepend on us.Business review02 At a glance06 Chairmans statement08 Chief Executive Officers review16 Business review22 Financial review26 Principal risks and uncertainties30 Corporate responsibility reportDirectors and governance36 Board of direct

2、ors38 Directors report43 Corporate governance54 Audit Committee report59 Nomination Committee report61 Remuneration Committee report76 Statement of directors responsibilities77 Independent auditors report to the members of BTG plcFinancials 80 Consolidated income statement81 Consolidated statement o

3、f comprehensive income82 Consolidated statement of financial position83 Consolidated statement of cash flows84 Consolidated statement of changes in equity85 Notes to the consolidated financial statements131 Company statement of financial position132 Company statement of cash flows133 Company stateme

4、nt of changes in equity134 Notes to the Company financial statements138 Appendix 1:Unaudited pro-forma consolidated income statement139 Five-year financial record141 Shareholder information143 Cautionary statement144 Trade marksContentsBusiness reviewBTG is a growing international specialist healthc

5、are company.Our mission is to bring to market medical products that meet the needs of specialist physicians and their patients.We are focused on three business areas:Specialty Pharmaceuticals,Interventional Medicine and Licensing&Biotechnology.Our products include a treatment for snakebites,antidote

6、s to treat toxicity associated with medicines used for heart conditions and cancer,and interventional oncology products that are used to treat patients with liver or prostate tumours.We develop our own products and we in-license or acquire them from others.We sell direct to our customers in the US a